YSOPIA - Model Yso3 - Preclinical Drug Development Program

Yso3 is a preclinical drug development program aimed at treating asthma. Using a revolutionary form of living biotherapy targeting the lung, YSOPIA is pioneering the innovative field of the lung microbiome. As part of this program, YSOPIA has selected a clinical candidate having demonstrated strong in vivo efficacy on inflammation and lung functions. We have achieved the formulation feasibility and cleared the regulatory hurdles associated with developing this new biotherapy. Continue our development plan to the clinical phase is the further step for this program.